Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
Table 6
Secondary outcome: efficacy and relationship with BMI in all patients.
Efficacy outcome
Rivaroxaban
Apixaban
Event rate (%)
value
Event rate (%)
value
Stroke in the AF cohort
BMI <25
1/25 = 4.0
1.000
0/31 = 0
0.574
BMI ≥25
4/102 = 3.9
3/94 = 3.2
BMI <30
3/68 = 4.4
1.000
1/70 = 1.4
0.582
BMI ≥30
2/59 = 3.4
2/55 = 3.6
TIA in the AF group
BMI 25
0/25 = 0
N/A
0/31 = 0
1.000
BMI ≥25
0/102 = 0
2/94 = 2.1
BMI <30
0/68 = 0
N/A
2/70 = 2.9
0.503
BMI ≥30
0/59 = 0
0/55 = 0
Recurrence in the VTE cohort
BMI <25
2/16 = 12.5
0.315
1/8 = 12.5
1.000
BMI ≥25
4/69 = 5.8
1/11 = 9.1
BMI <30
3/38 = 7.9
1.000
2/11 = 18.2
0.485
BMI ≥30
3/47 = 6.4
0/8 = 0
Chi-square and Fisher’s exact tests for efficacy outcomes (major bleeding, CRNMB and combined bleeding) in patients with BMI <25 versus ≥25 in both VTE and AF cohorts.
